Skip to main content
. 2022 Nov 24;12(12):1612. doi: 10.3390/brainsci12121612

Figure 3.

Figure 3

Spectrum of calcitonin gene-related peptide (CGRP) medications in clinical practice. The increase in migraine frequency per month is related to preventive therapy. Apparently, treatment is associated with a drug target that could be a receptor or ligand. Receptor target: erenumab, ubrogepant, rimegepant, and atogepant. Ligand target: fremanezumab, galcanezumab, and eptinezumab. PO: QoD, every other day; QD, daily; PRN, as needed; QLT, quarterly; QM, monthly.